295 related articles for article (PubMed ID: 11017864)
1. Emerging therapies for serious gram-positive bacterial infections: a focus on linezolid.
Plouffe JF
Clin Infect Dis; 2000 Sep; 31 Suppl 4():S144-9. PubMed ID: 11017864
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of linezolid versus comparator therapies in Gram-positive infections.
Wilcox MH
J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii27-35. PubMed ID: 12730140
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of linezolid in children.
Saiman L; Goldfarb J; Kaplan SA; Wible K; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S193-200. PubMed ID: 14520146
[TBL] [Abstract][Full Text] [Related]
4. [New treatment option for gram-positive infections in critically ill patients - overview over linezolid].
Krueger WA; Unertl KE
Anasthesiol Intensivmed Notfallmed Schmerzther; 2002 Apr; 37(4):199-204. PubMed ID: 11967745
[TBL] [Abstract][Full Text] [Related]
5. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
Stein GE; Wells EM
Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
[TBL] [Abstract][Full Text] [Related]
6. Linezolid: new preparation. In severe gram-positive infections.
Prescrire Int; 2003 Apr; 12(64):46-8. PubMed ID: 12669726
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of current agents used in the treatment of Gram-positive infections and the consequences of resistance.
Segreti J
Clin Microbiol Infect; 2005 May; 11 Suppl 3():29-35. PubMed ID: 15811022
[TBL] [Abstract][Full Text] [Related]
8. Linezolid for the treatment of infections caused by Gram-positive pathogens in China.
Lin DF; Zhang YY; Wu JF; Wang F; Zheng JC; Miao JZ; Zheng LY; Sheng RY; Zhou X; Shen HH; Ijzerman MM; Croos-Dabrera RV; Sheng W
Int J Antimicrob Agents; 2008 Sep; 32(3):241-9. PubMed ID: 18635341
[TBL] [Abstract][Full Text] [Related]
9. Role of linezolid in the treatment of complicated skin and soft tissue infections.
Peppard WJ; Weigelt JA
Expert Rev Anti Infect Ther; 2006 Jun; 4(3):357-66. PubMed ID: 16771613
[TBL] [Abstract][Full Text] [Related]
10. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.
Cepeda JA; Whitehouse T; Cooper B; Hails J; Jones K; Kwaku F; Taylor L; Hayman S; Shaw S; Kibbler C; Shulman R; Singer M; Wilson AP
J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840
[TBL] [Abstract][Full Text] [Related]
11. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens.
Jantausch BA; Deville J; Adler S; Morfin MR; Lopez P; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S164-71. PubMed ID: 14520142
[TBL] [Abstract][Full Text] [Related]
12. [The first clinical experiences in Hungary with a new effective antibiotic (linezolid) effective against Gram-positive infections].
Pulay I; Konkoly TM; Zsirka KA; Csapó Z; Flautner L; Tihanyi T
Orv Hetil; 2003 Jan; 144(1):29-33. PubMed ID: 12635350
[TBL] [Abstract][Full Text] [Related]
13. [Action in nosocomial pneumonia and severe skin and soft tissue infections. Linezolid in treatment].
Bodmann KF
Pharm Unserer Zeit; 2004; 33(1):38-41. PubMed ID: 14968711
[No Abstract] [Full Text] [Related]
14. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials.
Beibei L; Yun C; Mengli C; Nan B; Xuhong Y; Rui W
Int J Antimicrob Agents; 2010 Jan; 35(1):3-12. PubMed ID: 19900794
[TBL] [Abstract][Full Text] [Related]
15. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study.
Wilcox MH; Tack KJ; Bouza E; Herr DL; Ruf BR; Ijzerman MM; Croos-Dabrera RV; Kunkel MJ; Knirsch C
Clin Infect Dis; 2009 Jan; 48(2):203-12. PubMed ID: 19072714
[TBL] [Abstract][Full Text] [Related]
16. Experience with linezolid therapy in children with osteoarticular infections.
Chen CJ; Chiu CH; Lin TY; Lee ZL; Yang WE; Huang YC
Pediatr Infect Dis J; 2007 Nov; 26(11):985-8. PubMed ID: 17984803
[TBL] [Abstract][Full Text] [Related]
17. Linezolid: a new antibiotic for gram-positive infections.
Wilson P
Hosp Med; 2001 Nov; 62(11):682-6. PubMed ID: 11762099
[TBL] [Abstract][Full Text] [Related]
18. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.
Kaplan SL; Deville JG; Yogev R; Morfin MR; Wu E; Adler S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB;
Pediatr Infect Dis J; 2003 Aug; 22(8):677-86. PubMed ID: 12913766
[TBL] [Abstract][Full Text] [Related]
19. Use of linezolid in children: an overview of recent advances.
Velissariou IM
Expert Rev Anti Infect Ther; 2006 Dec; 4(6):947-52. PubMed ID: 17181410
[TBL] [Abstract][Full Text] [Related]
20. [Linezolid, the first oxazolidinone antibiotic].
Dutronc H; Bocquentin F; Galpérine T; Lafarie-Castet S; Dupon M
Med Mal Infect; 2005 Sep; 35(9):427-34. PubMed ID: 16297585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
